BENITIONSClinical Trial Intelligence

Exclusion of Intra-atrial Thrombus Before Catheter Ablation

단계 해당 없음 완료 NCT03455673

대상 질환Atrial Fibrillation, Thrombi
임상 단계단계 해당 없음
스폰서Groupe Hospitalier de la Rochelle Ré Aunis
상태완료
참여자 수3,160 명
중재(약물)ATE score
시작일2018년 9월 18일
완료일2020년 11월 7일
결과 공개일2023년 12월 22일

요약

Atrial fibrillation is the most frequent heart rhythm disorder. Its symptomatic forms, resistant to drug therapy, require invasive management (catheter ablation), which exposes to potentially serious complications including thromboembolic complications. Despite anticoagulant treatment, intra-atrial thrombus, which is a contraindication to catheter ablation, is detected in nearly 2 % of cases. Its diagnosis requires prior transoesophageal echocardiography, an unpleasant examination. A previous study (NCT02199080) showed that a zero ATE score, defined by no heart failure, no hypertension, no history of stroke, d-dimer \< 270 ng/mL, has a negative predictive value of 100 % for the exclusion of intra-atrial thrombus. The objective of the study is to confirm the negative predictive value, sensitivity and specificity of the ATE score for the exclusion of intra-atrial thrombus.

Number of Patients With Atrial Thrombus and a Zero ATE Score

at most 48 hours before ablation · Participants

Atrial Fibrillation2 Participants
Atrial Fibrillation816 Participants
Atrial Fibrillation27 Participants
Atrial Fibrillation2227 Participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.